Drug name - Azilect

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7815942 TEVA Rasagiline formulations of improved content uniformity
Aug, 2027

(4 years from now)

CN101123946B TEVA Rasagiline Formulations Of Improved Content Uniformity
Feb, 2026

(3 years from now)

CN101123946A TEVA Rasagiline Formulations Of Improved Content Uniformity
Feb, 2026

(3 years from now)

EP1848402B2 TEVA Rasagiline Formulations Of Improved Content Uniformity
Feb, 2026

(3 years from now)

EP1848402B1 TEVA Rasagiline Formulations Of Improved Content Uniformity
Feb, 2026

(3 years from now)

EP1848402A1 TEVA Rasagiline Formulations Of Improved Content Uniformity
Feb, 2026

(3 years from now)

EP1848402A4 TEVA Rasagiline Formulations Of Improved Content Uniformity
Feb, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572834 TEVA Rasagiline formulations and processes for their preparation Dec, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.